NIH cancer study on Nexrutine
This article was originally published in The Tan Sheet
Executive Summary
NIH's National Center for Complementary & Alternative Medicine awards two-year grant to AMC Cancer Research Center to study Next Pharmaceuticals' Nexrutine anti-inflammatory dietary supplement ingredient as a prostate cancer preventive agent, the Denver Colo.-based research institute announces Sept. 16. Nexrutine is a plant extract from bark of Phellodendron trees commonly found in Asia. AMC plans to determine the molecular mechanism underlying the ingredient's efficacy. Previous studies by Dr. Pratap Kumar, the proposal's principal investigator, found Nexrutine inhibits prostate cancer cell growth...
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.